AbbVie secured a $2.1 billion acquisition of Capstan Therapeutics, gaining access to its early-phase in vivo CAR-T platform targeting autoimmune and cancer indications. The purchase follows Capstan’s recent phase 1 trial initiation and represents AbbVie’s strategic expansion into cell-engineered therapies with potential manufacturing and delivery advantages over conventional CAR-T. The deal aligns with broader industry consolidation in cellular immunotherapy, emphasizing innovation in in vivo approaches.